GlassScriptPhysician profile
Richard Alan Macklin
NPI 1992436356
$1,117.40
in general payments reported to CMS, 2019-2025
19 companies · $161 in 2025
The $161 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $116 · 2023: $506 · 2024: $334 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,001.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $161.26 | 2024 | Symplicity G3 |
| E.R. Squibb & Sons, L.L.C. | $123.91 | 2023 | Camzyos |
| Otsuka America Pharmaceutical, INC. | $114.83 | 2023-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.22 | 2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $98.59 | 2022-2024 | Xarelto |
| Organogenesis INC. | $97.98 | 2023 | Puraply |
| Amgen INC. | $73.52 | 2025 | Repatha |
| Novo Nordisk INC | $53.13 | 2022-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $46.85 | 2022-2025 | Jardiance, Emgality |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $45.99 | 2025 | |
| Lundbeck LLC | $29.42 | 2023 | Rexulti |
| Exact Sciences Corporation | $26.00 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $25.87 | 2025 | Keytruda |
| Kyowa Kirin, INC. | $23.93 | 2024 | Crysvita |
| Glaxosmithkline, LLC. | $22.17 | 2024 | Shingrix, Arexvy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $20.39 | 2024 | |
| Ucb, INC. | $19.96 | 2024 | Bimzelx |
| Bayer Healthcare Pharmaceuticals INC. | $16.72 | 2024 | |
| Currax Pharmaceuticals LLC | $14.66 | 2023 | Contrave, Onzetra Xsail |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Macklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.